Premium
P2–253: Serotonin receptor binding in mild cognitive impairment studied by PET and [18f]–altanserin
Author(s) -
Hasselbalch Steen G.,
Madsen Karine,
Svarer Claus,
Pinborg Lars,
Stokholm Jette,
Holm Soeren,
Paulson Olaf B.,
Waldemar Gunhild,
Knudsen Gitte M.
Publication year - 2006
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2006.05.1092
Subject(s) - putamen , medicine , serotonergic , positron emission tomography , binding potential , neuropsychology , cognitive impairment , alzheimer's disease , endocrinology , serotonin , caudate nucleus , psychology , nuclear medicine , receptor , cardiology , neuroscience , cognition , disease
brain (WB), as predictors and correlates of clinical status, and their incremental accuracy over the parieto-temporal and posterior cingulate cortices. Results: At baseline, reductions in Hip, Amy, and WB MRglc were found for NL-MCI, MCI and AD as compared to NL-NL (p .05). The NL-MCI had Hip (17%, p ), WB (14%) and Amy (8%, p ) MRglc reductions that were comparable to those observed in clinical MCI patients (19%, 16% and 11%, respectively). These MRglc measures predicted decline from NL to MCI with accuracies of 81% (Hip), 67% (WB), and 65% (Amy). No differences in baseline cortical MRglc were found between NL-MCI and NL-NL, whereas the MCI group showed reduced temporal cortex MRglc, and the AD group showed the typical parietal, temporal, and posterior cingulate cortex hypometabolism (p .05, corrected). Longitudinally, Hip MRglc highly correlated with clinical progression with greater rates of annual reductions in the following order: AD (3.7%) MCI (2.9%) NLMCI (2.1%) NL-NL(1.2%). Conclusions: Years prior to clinical change, NL subjects destined to decline to MCI show a PET profile intermediate between normal aging and MCI, characterized by early WB and MTL MRglc reductions. These findings show that PET MRglc measures are predictors and correlates of cognitive impairment, and may help identify subjects at risk for future AD.